陳 怡仁

Medicine & Life Sciences

1. Endometriosis 100%
2. Taiwan 91%
3. Myoma 82%
4. Ovarian Epithelial Carcinoma 82%
5. Uterine Myomectomy 78%
6. Induced Pluripotent Stem Cells 71%
7. Uterine Cervical Neoplasms 64%
8. Adenomyosis 64%
9. Carcinoma 61%
10. Endometrial Neoplasms 57%
11. Pregnancy 55%
12. Neoplasms 54%
13. Fallopian Tubes 54%
14. Laparoscopy 48%
15. Ovarian Neoplasms 47%
16. Systematic Reviews 47%
17. Estrogens 45%
18. Cystectomy 43%
19. Morcellation 42%
20. Cisplatin 41%
21. Leiomyoma 39%
22. Ovarian Teratoma 39%
23. Suburethral Slings 36%
24. Sarcoma 34%
25. Therapeutics 34%
26. Gynecologic Surgical Procedures 33%
27. Recurrence 33%
28. Teratoma 32%
29. Cyclooxygenase 2 31%
30. Drug Therapy 31%
31. beta-D-galactoside alpha 2-6-sialyltransferase 31%
32. Gestational Age 30%
33. Fallopian Tube Neoplasms 29%
34. Levonorgestrel 27%
35. Retrospective Studies 26%
36. Shoulder Pain 25%
37. Survival 25%
38. Menorrhagia 24%
39. Squamous Cell Carcinoma 24%
40. Carcinosarcoma 24%
41. Gynecology 24%
42. Operative Time 23%
43. Endometrium 23%
44. Paclitaxel 23%
45. Randomized Controlled Trials 22%
46. Abdominal Pain 22%
47. Gonadotropin-Releasing Hormone 22%
48. Breast Neoplasms 21%
49. Cohort Studies 21%